0001209191-23-041617.txt : 20230706
0001209191-23-041617.hdr.sgml : 20230706
20230706172059
ACCESSION NUMBER: 0001209191-23-041617
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230703
FILED AS OF DATE: 20230706
DATE AS OF CHANGE: 20230706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fenton Mary Kay
CENTRAL INDEX KEY: 0001378589
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40384
FILM NUMBER: 231074488
MAIL ADDRESS:
STREET 1: ACHILLION PHARMACEUTICALS
STREET 2: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Talaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001827506
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 570 PRESTON ST.
STREET 2: SUITE 400
CITY: LOUISVILLE
STATE: KY
ZIP: 40202
BUSINESS PHONE: 502-398-9250
MAIL ADDRESS:
STREET 1: 93 WORCESTER STREET
CITY: WELLESLEY
STATE: MA
ZIP: 02481
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-07-03
0
0001827506
Talaris Therapeutics, Inc.
TALS
0001378589
Fenton Mary Kay
C/O TALARIS THERAPEUTICS, INC.
93 WORCESTER ST.
WELLESLEY
MA
02481
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-07-03
4
F
0
12946
3.08
D
68054
D
The restricted stock units ("RSUs") were granted to the Reporting Person by the issuer under the Issuer's 2021 Stock Option and Incentive Plan on September 10, 2022. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. This transaction reflects the sufficient shares sold to pay applicable income taxes related to the 50% vesting on July 1, 2023.
/s/ Mary Kay Fenton
2023-07-06